Subsequent Event (Details Textual) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	6 Months Ended
	Aug. 10, 2015	Aug. 07, 2015	Jul. 21, 2015	Jun. 30, 2015
Proceeds from Issuance Initial Public Offering			$ 42.6
Stock Issued Price Per Share			$ 3.00
Proceeds From Issuance Initial Public Offering Gross			$ 46.0
Stock Issued During Period Shares, Options Exercised To Underwriters			2,000,000
Stock Issued During Period, Shares, Public Offering			15,300,000
Licensing Agreements [Member]
License Development Cost				$ 14.0
Additional Development Cost For License Agreement				$ 4.0
Sublicense Percentage				25.00%
Sales Revenue, Net [Member] | Licensing Agreements [Member]
Royalty Earned Percentage				7.00%
Intrexon [Member]
Milestone Payment	$ 27.0
Stock Issued During Period, Value, New Issues		$ 3.0
Stock Issued During Period, Shares, New Issues		937,500
Intrexon [Member] | Maximum [Member]
Royalty Expense	100.0
Intrexon [Member] | Minimum [Member]
Royalty Expense	$ 750.0
Development Partner [Member] | Sales Revenue, Net [Member] | Licensing Agreements [Member]
Revenue Recognition, Milestone Method, Revenue Recognized				$ 100.0
Milestone Payments Description				In consideration of the rights received, Licensee agreed to additional one-time milestone payments (for Licensee’s achievement of certain milestone events) of (i) $2 million upon dosing the first patient in the first Phase 3 clinical trial; (ii) $3 million upon filing a New Drug Application (an “NDA”) with the FDA for a Licensed product; (iii) $1.5 million upon approval by the FDA of the NDA; (iv) $1.5 million upon achievement of $50 million in annual Net Sales (as defined in the License Agreement) for a License Product; and (v) $3 million upon achievement of $100 million in annual Net Sales for a Licensed Product. The Licensee also agreed to pay to The Regents 40% of sublicensing income payments received based on sublicensing, which includes all consideration received from a Sublicensee (as defined in the License Agreement) including milestone payments, sales-based payments, upfront license payments, but subject to certain exceptions; provided , however sublicensing fee payments will not be less than 5% of the Net Sales of the Licensed Products or Licensed Methods (as defined in the License Agreement) by the Sublicensee or other specified entities.